Table 2 The cost and outcome results of the cost-effectiveness analysis.

From: Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China

Group

C ($)

Incr C

E (QALY)

Incr E

ICER($/QALY)

R-CHOP

31015.38

 

5.59

  

Pola-R-CHP

62819.42

31804.04

5.88

0.29

110593.81

  1. Abbreviations: Pola-R-CHP, polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; C, cost; E, effectiveness; Incr C, Incremental Cost; Incr E, Incremental Effectiveness; ICER, Incremental Cost-Effectiveness Ratio.
Back to article page